Microbot Medical Inc. (Nasdaq: MBOT) has received FDA clearance for the LIBERTY Endovascular Robotic System.
The clearance allows the company to commercialize LIBERTY in the U.S. and aims to revolutionize endovascular robotics.
The pivotal study of LIBERTY showed 100% success in robotic navigation and significant benefits for healthcare providers.
FDA Clearance Achieved
Microbot Medical obtained FDA 510(k) clearance for the LIBERTY Robotic System, a milestone for the company.
Market Entry Acceleration
With the clearance in place, Microbot is well-positioned to enter the U.S. market for peripheral endovascular procedures.
Clinical Success
LIBERTY's pivotal study demonstrated impressive robotic navigation success rates and reduced radiation exposure for physicians.
- The FDA clearance marks a significant milestone for Microbot Medical, paving the way for commercialization and market penetration.
- LIBERTY's innovative design and clinical success are expected to enhance procedure efficiency, lower costs, and improve healthcare quality.
Microbot Medical's achievement of FDA clearance for the LIBERTY Robotic System sets the stage for the company's commercial success and advancements in endovascular care.